Cambridge Healthtech Institute’s 5th Annual
Next-Generation Immunotherapies
In vivo CAR T Engineering, New Targets, and Beyond
May 14-15, 2026
The immunotherapy field has achieved extraordinary breakthroughs in recent years, yet major challenges remain in targeting, delivery, and efficacy. Cambridge Healthtech Institute’s 5th annual Next-Generation Immunotherapies conference will spotlight the latest wave of immune reprogramming platforms—from in vivo CAR T engineering and AI/ML-driven design to targeting dark antigens, novel cancer therapies, genome editing, and emerging delivery technologies. Join leading experts as they share cutting-edge strategies poised to transform cancer and autoimmune treatment.
Coverage will include, but is not limited to:
In vivo Engineering of the Immune System: CAR T and Beyond
- Latest developments in in vivo CAR T—clinical and preclinical updates
- Therapeutic area applicability: Oncology, autoimmune diseases and regenerative medicine
- Comparing viral (lenti) vs. RNA platforms—what do the recent acquisitions and collabs tell us
- Next-generation in vivo engineering and delivery beyond CAR T payloads (PD-1s)
- Engineering strategies to improve specificity and reduce off-target toxicity
- Clinical, regulatory path, CMC, and commercial considerations
Next Generation Immunotherapies
- Advances in mRNA cancer therapes
- Cancer vaccines in combination with CAR T
- Oncolytic viruses
- Novel delivery methods
- Oligonucleotides, RNAi conjugates
- Nanomedicine
- Latest advances in cancer vaccines
- Updates from key players
- Oncolytic Viruses—where is the industry going? What are the bottlenecks?
AI/ ML Approaches for Developing Next-Generation Immunotherapies
- Genome screening for identifying new targets
- Leveraging AI and machine learning to identify novel immunotherapy targets and MOAs
- Computational engineering of antibody domains, TCE affinity, and CAR constructs for improved safety, persistence, and stability
Dark Genome Targeting and Discovery of New Immunotherapies
- Illuminating the Dark Antigen Landscape: Next-Generation Strategies for Immunotherapy
- Expanding Beyond Surface Antigens—Unlocking intracellular oncogenes and tumor suppressors through TCR-based and pHLA-targeting engagers.
- Novel Target Discovery Platforms—Leveraging surfaceome profiling, multi-omics, and AI to identify underexplored immunotherapy targets.
- Engineering for Specificity and Safety—Strategies to overcome HLA restriction, antigen escape, and off-tumor risks.
- Translating Dark Antigens into Therapies—Case studies in KRAS, p53, and viral-driven cancers demonstrating clinical potential.
The deadline for priority consideration is October 17, 2025.
AAll proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: